Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2021-08-09 Board/Management Inform…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC Board Changes 2 pages 124.4KB
Board/Management Information Classification · 100% confidence The document is an announcement dated 10 August 2021 from Cyclopharm Limited to the Australian Securities Exchange. It announces the appointment of Ms Dianne Angus as a Non-Executive Director to the Board of Directors. The content focuses on the new board member's background and the company's strategic outlook. There are no financial statements, earnings data, or detailed report content. The document length is 3508 characters, which is relatively short and typical for a management or board change announcement. Therefore, this document fits the category of Board/Management Information (MANG).
2021-08-09 English
Initial Director's Interest Notice 2 pages 144.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial interests of a newly appointed director in the company's securities, including sections on securities held and interests in contracts, all of which are nil in this case. This type of document is a report of personal share transactions or interests by company directors, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not on broader financial or management information. Therefore, the correct classification is Director's Dealing (DIRS).
2021-08-09 English
CYC First Half Trading Update 3 pages 151.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 2 July 2021 from Cyclopharm Limited providing an update on its trading performance for the first half of 2021. It includes unaudited management account highlights such as expected revenue figures, growth percentages compared to prior periods, cash reserves, and dividend intentions. The document explicitly states that the company anticipates announcing further information in its 1H 2021 results announcement scheduled for late August 2021. The content is a trading update and preliminary financial performance summary rather than a full interim or quarterly report containing actual financial statements or detailed analysis. Therefore, it fits best as a Capital/Financing Update (CAP) since it provides an update on financial performance and dividend expectations without full financial disclosures or statements. The document length (5826 characters) and content confirm it is not a full Interim Report (IR) or Annual Report (10-K).
2021-07-01 English
Cyclopharm USFDA Update 3 pages 134.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) related to their New Drug Application (NDA) for Technegas. It discusses regulatory feedback, outstanding technical issues, and revised timelines for approval. The content is focused on regulatory and approval process updates rather than financial results, management changes, or shareholder information. The document is about a regulatory update and does not contain financial statements or detailed financial data. It is not a report itself but an announcement about regulatory progress and timelines. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2021-06-27 English
Ceasing to be a substantial holder from MUFG 2 pages 800.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests of a substantial shareholder, Mitsubishi UFJ Financial Group, Inc., including dates and particulars of shareholding changes. This type of filing is a notification about changes in significant share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification (MRQ). The document length is 4427 characters, which is consistent with a detailed notification rather than a brief announcement or a full report. Therefore, the correct classification is MRQ with high confidence.
2021-06-06 English
Becoming a substantial holder from MS 7 pages 343.5KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder' and details the substantial shareholding of Morgan Stanley and its subsidiaries in Cyclopharm Limited. It includes voting power percentages, relevant interests, registered holders, consideration paid for shares, and associates. This is a formal notification of a substantial shareholding interest as required under the Corporations Act, which is a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory filing specifically about share ownership thresholds being crossed.
2021-06-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.